Hers vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

MEDVi beats Hers overall, scoring 7.7/10 vs 7.3/10. Hers is more affordable at $199/mo vs $299/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose MEDVi for users who want a low entry price with oral and injectable co.

A side-by-side comparison of Hers and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Higher Rated

MEDVi

#22 of 48

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake — one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Feature	Hers	MEDVi
Our Score	7.3/10	7.7/10
Starting Price	$199/mo	$299/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand	Users who want a low entry price with oral and injectable compounded options
Ranking	#35	#22

Pros & Cons Compared

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Our Verdict

MEDVi edges out Hers with a score of 7.7/10 vs 7.3/10. If budget is your priority, Hers starts at $199/mo compared to MEDVi's $299/mo. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Hers nor MEDVi feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review